Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
| ▸ | HTR1D | P28221 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 3/20 | 0.35 |
| ▸ | ACVR1B | P36896 | 4/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429640 | 0.83 | HTR2C (0.51) | PDK2PDK4HTR1AHTR1DSLC6A4 | |
| SCHEMBL13525142 | 0.73 | HTR1A (0.54) | PDK2PDK4HTR1AHTR1DSLC6A4 | |
| SCHEMBL5759614 | 0.71 | MTNR1A (0.44) | HTR2CCYP1A2 | |
| SCHEMBL5759610 | 0.71 | MTNR1A (0.44) | HTR2CCYP1A2 | |
| SCHEMBL5759605 | 0.71 | MTNR1A (0.44) | HTR2CCYP1A2 | |
| SCHEMBL6595010 | 0.69 | SLC6A4 (0.41) | HTR1ASLC6A4HTR2CPLG | |
| SCHEMBL6599216 | 0.69 | SLC6A4 (0.42) | HTR1ASLC6A4HTR2CPLG | |
| SCHEMBL6599220 | 0.69 | SLC6A4 (0.42) | HTR1ASLC6A4HTR2CPLG | |
| SCHEMBL6595014 | 0.69 | SLC6A4 (0.41) | HTR1ASLC6A4HTR2CPLG | |
| SCHEMBL6599214 | 0.69 | SLC6A4 (0.42) | HTR1ASLC6A4HTR2CPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| CN-101048414-B | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD | 2011-09-07 | — | — | CN | disclosed |
| CN-101048414-A | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD (GB) | 2007-10-03 | — | — | CN | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | PDK2 1399/4885PDK4 1468/4885HTR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.